JP2006501249A - ワクチン - Google Patents

ワクチン Download PDF

Info

Publication number
JP2006501249A
JP2006501249A JP2004532301A JP2004532301A JP2006501249A JP 2006501249 A JP2006501249 A JP 2006501249A JP 2004532301 A JP2004532301 A JP 2004532301A JP 2004532301 A JP2004532301 A JP 2004532301A JP 2006501249 A JP2006501249 A JP 2006501249A
Authority
JP
Japan
Prior art keywords
immunogen
vaccine
sequence
human
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004532301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006501249A5 (https=
Inventor
エリス，ジョナサン，ヘンリー
アシュマン，クレア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0220211A external-priority patent/GB0220211D0/en
Priority claimed from GB0304672A external-priority patent/GB0304672D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2006501249A publication Critical patent/JP2006501249A/ja
Publication of JP2006501249A5 publication Critical patent/JP2006501249A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2004532301A 2002-08-30 2003-08-28 ワクチン Pending JP2006501249A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0220211A GB0220211D0 (en) 2002-08-30 2002-08-30 Vaccine
GB0304672A GB0304672D0 (en) 2003-02-28 2003-02-28 Vaccines
PCT/GB2003/003729 WO2004019975A2 (en) 2002-08-30 2003-08-28 Il-14 vaccine for the treatment of asthma and atopic disorders

Publications (2)

Publication Number Publication Date
JP2006501249A true JP2006501249A (ja) 2006-01-12
JP2006501249A5 JP2006501249A5 (https=) 2006-06-15

Family

ID=31980002

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004532301A Pending JP2006501249A (ja) 2002-08-30 2003-08-28 ワクチン
JP2004532296A Pending JP2006503018A (ja) 2002-08-30 2003-08-28 ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004532296A Pending JP2006503018A (ja) 2002-08-30 2003-08-28 ワクチン

Country Status (6)

Country Link
US (1) US20060104943A1 (https=)
EP (2) EP1534323A2 (https=)
JP (2) JP2006501249A (https=)
AU (2) AU2003260748A1 (https=)
CA (2) CA2496948A1 (https=)
WO (2) WO2004019975A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509321A (ja) * 2006-11-13 2010-03-25 セラヴァック ファーマスウティカルズ エイ ビー 種々の炎症状態の治療用の新規な組成物
JP2021525726A (ja) * 2018-05-29 2021-09-27 ネオヴァクス 異常なｉｌ−４および／またはｉｌ−１３の発現または活性に関連する疾患を治療するためのｉｌ−４および／またはｉｌ−１３を含む免疫原性産物

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06000258A (es) * 2003-07-15 2006-07-03 Cambridge Antibody Tech Moleculas de anticuerpo humano para interleucina-13.
PL3718564T3 (pl) 2003-12-23 2024-03-18 Genentech, Inc. Nowe przeciwciała anty-IL 13 i ich zastosowania
US20070048785A1 (en) * 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
GB0600488D0 (en) * 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
WO2008109957A1 (en) * 2007-03-15 2008-09-18 Hunter Immunology Limited Method for determining suitability of treatment for asthma or chronic airways disease
CN101657214B (zh) * 2007-03-15 2013-01-09 亨特免疫有限公司 哮喘的治疗或预防
CN120904322A (zh) 2013-09-13 2025-11-07 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
JP2024504194A (ja) * 2021-01-29 2024-01-30 エランコ アニマル ヘルス ゲー・エム・ベー・ハー 自己寛容を破壊するためのワクチン組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6296843B1 (en) * 1998-04-03 2001-10-02 The Penn State Research Foundation Mutagenized IL 13-based chimeric molecules
HUP0200958A3 (en) * 1999-04-23 2004-11-29 Pharmexa As Method for down-regulating il5 activity
TR200400621T2 (tr) * 1999-07-20 2004-08-23 Pharmexa A/S GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem.
EP1263785A2 (en) * 1999-11-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mutated il-13 molecules and their uses
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
AU2002244337B2 (en) * 2000-10-18 2005-08-11 Glaxosmithkline Biologicals S.A. Vaccines
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
JP2006503017A (ja) * 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド Ｉｌ−１３要素及びｔ細胞エピトープを含む免疫原組成物並びにその治療上の使用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509321A (ja) * 2006-11-13 2010-03-25 セラヴァック ファーマスウティカルズ エイ ビー 種々の炎症状態の治療用の新規な組成物
JP2021525726A (ja) * 2018-05-29 2021-09-27 ネオヴァクス 異常なｉｌ−４および／またはｉｌ−１３の発現または活性に関連する疾患を治療するためのｉｌ−４および／またはｉｌ−１３を含む免疫原性産物
JP7291729B2 (ja) 2018-05-29 2023-06-15 ネオヴァクス 異常なｉｌ－４および／またはｉｌ－１３の発現または活性に関連する疾患を治療するためのｉｌ－４および／またはｉｌ－１３を含む免疫原性産物

Also Published As

Publication number Publication date
WO2004019975A2 (en) 2004-03-11
AU2003259374A1 (en) 2004-03-19
CA2496948A1 (en) 2004-03-11
AU2003260748A8 (en) 2004-03-19
AU2003259374A8 (en) 2004-03-19
CA2496607A1 (en) 2004-03-11
AU2003260748A1 (en) 2004-03-19
WO2004019975A3 (en) 2004-07-08
US20060104943A1 (en) 2006-05-18
JP2006503018A (ja) 2006-01-26
WO2004019979A2 (en) 2004-03-11
EP1534329A2 (en) 2005-06-01
WO2004019979A3 (en) 2004-07-08
EP1534323A2 (en) 2005-06-01

Similar Documents

Publication Publication Date Title
AU2006222225B2 (en) Varicella zoster virus vaccine
JP6938487B2 (ja) ワクチン
JP4238031B2 (ja) ワクチン
EA015551B1 (ru) Конъюгатные вакцины
CN105120892B (zh) 包含艰难梭菌cdtb和/或cdta蛋白的元件的免疫原性组合物
JP2006503017A (ja) Ｉｌ−１３要素及びｔ細胞エピトープを含む免疫原組成物並びにその治療上の使用
JP2006501249A (ja) ワクチン
JP2008019262A (ja) Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのための免疫原性組成物
WO2007113633A2 (en) Immunogenic compositions comprising cat allergen fel dl
AU2002233560A1 (en) Vaccine
TW201309327A (zh) 疫苗
US20070048261A1 (en) Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases
KR20020084841A (ko) Ｉｌ5 활성을 다운-조절하는 방법
JP2019515957A (ja) イヌアトピー性皮膚炎の治療
WO2004052395A1 (en) L2-peptide of the human papillomavirus associated with virus-like particles
JP2011103893A (ja) 組換えインフルエンザ菌アドヘシンタンパク質
CN111533792B (zh) 一种定点突变的载体蛋白及其在制备疫苗中的用途
EP1532168A2 (en) Method for refolding neisserial nspa protein
JP2002532433A (ja) インフルエンザ菌由来の少なくとも２つの抗原を含む、疾病予防のための多成分ワクチン
JP2022544407A (ja) 免疫原性組成物
WO2025077785A1 (zh) 一种抗脑膜炎球菌的免疫组合物及其用途
WO2023014245A1 (ru) Состав вакцины против covid-19 vaccine composition against covid-19
TW201348264A (zh) 組成物
CN112912097A (zh) 免疫原性蛋白和组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090901

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100209